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Abstract Thyroid hormones (THs) play a crucial role
in the homeostasis of muscle function, such as
myogenesis and energy metabolism, suggesting that
the thyroid may be also involved in the entropic pro-
cesses of muscle aging. The aim of the present study is
to evaluate the effect of TH signaling on physical per-
formance, muscle mass, and strength in a cohort of
community-dwelling oldest-old subjects (> 90 years).
The study population was selected in a rural area of
central Italy (Mugello, Tuscany), and the design was
cross-sectional. Four hundred seventy-five subjects
(130 males and 345 females) were enrolled,
representing about 65% of all the nonagenarians living
in the Mugello area. After adjusting for multiple con-
founding factors (sex, age, diabetes, and levothyroxine
administration), the lowest quartile of FT3/FT4 ratio
distribution showed lower physical performance com-
pared to the other quartiles (β ± SE: − 0.49 ± 0.12;
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p < 0.001), whereas the highest quartile of FT3/FT4
ratio was associated with higher skeletal muscle index
(β ± SE: 1.11 ± 0.42; p = 0.009). In addition, the lowest
quartile of FT4 showed a statistically significant higher
handgrip strength (β ± SE: 1.78 ± 0.68; p = 0.009) com-
pared to all other quartiles. This study demonstrates that
nonagenarians with higher FT3/FT4 ratios had better
preserved muscle function, therefore successfully over-
coming the imbalance of homeostatic and entropic pro-
cesses involved inmuscle aging. However, we could not
establish a cause-effect relationship due to the cross-
sectional design of the study.
Keywords Thyroid hormone signaling .Aging .Oldest-
old . Physical performance .Musclemass .Muscle
strength . Rehabilitation
Introduction
In 2050, it is expected that one in six people worldwide
will be aged 65 years or over [1]. Aging is a natural
process that may present a decline in the functional
status of patients and is a common cause of subsequent
disability [2]. Musculoskeletal, neurological, circulato-
ry, or sensory conditions can lead to a decrease in
physical function [3–5].
Longitudinal studies have demonstrated that fat mass
increases, whereas muscle mass, strength, and physical
performance progressively decline during aging, even if
with different rates of progression [6, 7]. Several factors
have been hypothesized as determinants of those chang-
es; among them are diseases, physical inactivity, inflam-
mation, malnutrition, reduced metabolic rate, and hor-
monal imbalance [8–10]. All these processes may occur
as part of a common pathway or may be interrelated, for
example, aging people with a lower metabolic rate have
a significantly lower level of multiple morbidities, and
they are healthier than those with a higher metabolic rate
[11]. If reduced metabolism is a protective mechanism,
it may explain why people who have lower free triiodo-
thyronine (FT3) and free thyroxine (FT4) and also have
a lower FT3/FT4 ratio are still alive at an older age [12,
13]. The increase of FT3 production from FT4 due to the
action of TSH becomes less pronounced with aging and
may be completely lost in the elderly [12]. This could
reflect either reduction in deiodinase (DIO) activity with
age, and/or development of thyroid hormone resistance
with increasing age [14]. In an euthyroid population
(40–69 years) from Korea, low serum FT3/FT4 was
found to be a reliable index for low muscle mass and
impaired physical performance [15]. Similar results
were found in a cohort of centenarians and offspring,
where THs levels predict disability, mortality, and cog-
nitive level [13]; in another recent work in the same
cohort THs, specifically FT3/FT4 ratio, levels were
inversely associated with frailty score [16].
Moreover, thyroid hormone off-label supplementa-
tion, in euthyroid subjects, was tested in different con-
ditions [17], but levothyroxine (LT4) does not reverse
the nonspecific symptoms [18].
The aim of the present study is to evaluate the effect
of thyroid hormone signaling on physical performance,
muscle mass, and strength in a cohort of community-
dwelling oldest-old subjects (> 90 years).
Methods
The design of the Mugello study has been described in
detail elsewhere [19]. Briefly, the study was designed
and conducted by the Department of Experimental and
Clinical Medicine, University of Florence, Italy, and by
the Don Carlo Gnocchi Foundation (Florence, Italy).
The study was performed in the Mugello area, a wide-
spread valley northeast of Florence, in the Tuscany
region. The study was designed as a cross-sectional
survey, and data were collected in 2009.
Samples
Of the 475 subjects (130 men and 345 women) enrolled
in the study, representing approximately 65% of the
nonagenarians living in the Mugello area, 417 subjects
who consented to donate a blood sample and had all the
variables of interest were included. A small group of
institutionalized nonagenarians were also included.
There was no exclusion criterion. The study protocol,
which complied with the principles of the Declaration of
Helsinki on clinical research involving human subjects,
was approved by the Institutional Review Board. All
participants, or proxies, signed the informed consent
form to be included in the study.
Home interview
A trained interviewer investigated family, medical, and
medication history. In particular, family history of
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cardiovascular, cerebrovascular, and respiratory dis-
eases; cancer; and dementia was obtained. Past and
recent medical history was recorded using a semi-
structured questionnaire.
Comprehensive geriatric assessment
Some specific geriatric items, such as functional inde-
pendence, physical activity level, quality of life, mood,
sleep quality, and falls, were assessed.
Clinical assessment
The interview was followed by a general physical and
clinical examination with special attention to general
and neurological condition, by a semi-structured ques-
tionnaire. Anthropometric measures, such as weight,
height, ulna length, lower limb length (from the
anterior–superior iliac spine to the internal malleolus),
abdominal and hip circumference, as well as arm, thigh,
and leg circumference, were also recorded.
Body composition
Body composition was assessed by using Body Imped-
ance Assessment (BIA) (EFG, Akern, Italy). BIA mea-
sures the opposition of body tissues to the flow of a
small (less than 1 mA) alternating current by providing
two values (resistance and reactance). Muscle mass was
calculated using the Sergi equation [20]. Skeletal muscle
index (SMI) was obtained from the standardization of
the absolute skeletal muscle mass per squared meters,
calculated through the Janssen and colleagues equation
[21].
Physical performance
The short physical performance battery (SPPB)
based on the lower extremity performance tests used
in the Established Populations for the Epidemiologic
Studies of the Elderly (EPESE) was used here to
summarize lower extremity performance [22]. The
SPPB consisted of walking speed, ability to stand
from a chair, and ability to maintain balance in
progressively more challenging positions. A score
ranging from zero, representing inability to do the
test, to one, representing the highest level of perfor-
mance, was calculated from the three physical per-
formance tasks. The score in every timed-task was
calculated as the inverse of the percentage, where
the worst time is the unity. Lastly, the three mea-
sures were added to create a summary physical
performance measure ranging from zero (worst) to
three (best). This approach for the calculation of the
performance was needed since specific age adjusted
cutoff points are not available; therefore the classic
way to calculate the SPPB score could produce left-
skewed data.
Handgrip test
Handgrip strength was measured using a handheld dy-
namometer (Hydraulic Dynamometer, RO+TEN, Italy).
Participants were asked to perform the task twice with
each hand. The average of the best result obtained with
each hand was used for these analyses.
Blood collection
Finally, about 1 week after the clinical assessment, a
nurse collected venous blood samples for routine and
special laboratory tests. Serum and plasma aliquots were
also stored at − 80° in the biologic bank.
Laboratory tests
Serum levels of thyroid-stimulating hormone (TSH)
were measured using an enzyme-linked immunosorbent
assay (ELISA), with the WHO First International Ref-
erence Standard, and a sensitivity of 0.08 μg/mL; a
colorimetric competitive immunoassay was used to
measure T3 and T4 with purified protein standard and
polyclonal anti-T3 and anti-T4 (Diesse Diagnostica
Senese, Chorus fT3, fT4, TSH, Monteriggioni, Siena,
Italy); serum creatinine level was assessed using a stan-
dard creatinine Jaffe method (Roche Diagnostics,
GmbH, Mannheim, Germany), which had an inter-
assay coefficient below 2.5%.
Statistical analysis
Cross-sectional characteristics were compared between
quartiles of distribution of FT3, FT4, TSH, and FT3/
FT4 ratio, for all the variables of interest; differences
among quartiles were evaluated using analysis of vari-
ance for continuous variables and χ2 test analyses for
dichotomous or categorical variables.
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To analyze whether statistically significant differ-
ences could be found in the mean values of SPPB score,
handgrip test, and muscle mass/height squared, between
subjects in the THs quartiles of distribution, linear re-
gression models were used, adjusting for age and sex.
Lastly, to evaluate the independent but concurrent
role of different markers of thyroid signaling hormones
on physical performance, strength, and muscle mass,
three separate linear regression models were analyzed.
Only dummy quartile derived variables were consid-
ered, and the different models were adjusted for age,
sex, diabetes, and levothyroxine therapy, and variables
were not excluded from the model even if they did not
reach a statically significant level.
The backward selection was made visually on the p
value basis. AIC, R2, and RSSE goodness of fit tests
were assessed to discriminate variables better describing
the different associations in the parsimonious model
[23].
Analyses were conducted using SAS 9.4 (SAS Insti-
tute Inc., Cary, NC, USA).
Results
Four hundred seventeen subjects were enrolled in
this study; 111 (26.62%) were males, and the
mean age of the total population was 93.00 ±
3.16 years, with slightly but significantly younger
age in males (M = 92.37 ± 2.66 years; F = 93.22 ±
3.30; p = 0.01).
Basic participant characteristics were found to be
similar when the variables were analyzed according to
TSH levels ranked in quartiles, the only exception being
the ratio of muscle mass/height squared ratio, which
increased from the lowest quartile to the highest one
(p = 0.04) (Table 1).
A similar trend was found for distribution in quartiles
of the values of serum FT3 (Table 2). In this case too,
muscle mass/height squared ratio showed a linear in-
crease through the different quartiles (Stβ ± SE = 0.11 ±
0.05). An increase of the SPPB score from lowest
through highest quartile was also observed (Stβ ± SE =
0.17 ± 0.05).
Table 1 Descriptive of the population enrolled in the Mugello study according to quartiles of TSH (μIU/mL) distribution
TSH < 0.79 TSH 0.80–1.25 TSH 1.26–2.11 TSH > 2.11
106 103 104 104 p trend
Sex male n (%) 28 (26.4) 34 (33.3) 27 (26.0) 22 (21.2) 0.27
Age (yy) 93.03 ± 3.40 92.87 ± 3.05 92.88 ± 3.36 93.22 ± 2.85 0.68
Weight (kg) 60.53 ± 11.48 61.62 ± 12.54 62.77 ± 12.78 62.44 ± 13.46 0.22
Height (m) 1.56 ± 0.08 1.58 ± 0.10 1.57 ± 0.10 1.57 ± 0.08 0.74
Smoke (actually) 26 (24.5) 35 (34.3) 29 (27.9) 26 (25.0) 0.15
Diabetes 11 (10.3) 12 (11.8) 20 (19.2) 14 (13.5) 0.25
Cardiovascular diseases n (%) 49 (46.3) 46 (45.1) 48 (46.2) 47 (45.2) 0.97
Respiratory diseases n (%) 15 (14.2) 16 (15.7) 15 (14.4) 15 (14.4) 0.99
Cerebrovascular diseases n (%) 14 (13.2) 26 (25.5) 21 (25.5) 24 (23.1) 0.20
Dementia n (%) 15 (14.2) 11 (10.8) 11 (10.8) 13 (12.5) 0.82
Oncological diseases n (%) 53 (50.0) 65 (63.7) 53 (51.0) 55 (52.9) 0.52
SPPB (0–3) 1.15 ± 1.07 1.24 ± 1.10 1.17 ± 1.03 1.12 ± 1.05 0.74
Handgrip (kg) 13.20 ± 6.73 13.88 ± 8.12 13.97 ± 6.38 12.49 ± 7.06 0.56
Levothyroxine 2 (1.9) 4 (3.9) 1 (0.9) 11 (10.6) 0.003
Muscle/height2 (kg/m2) 11.51 ± 3.38 11.76 ± 2.72 12.01 ± 3.01 12.52 ± 3.13 0.04
Fat mass (kg) 15.89 ± 8.50 14.50 ± 8.22 16.29 ± 10.53 16.60 ± 9.75 0.44
FT3 (pg/m) 2.98 ± 0.69 2.86 ± 0.34 2.79 ± 0.39 2.76 ± 0.45 0.001
FT4 (ng/dL) 0.95 ± 0.29 0.91 ± 0.19 0.85 ± 0.17 0.81 ± 0.22 0.001
TSH (μIU/mL) 0.50 ± 0.23 1.01 ± 0.14 1.62 ± 0.25 5.42 ± 9.87 0.001
FT3/FT4 ratio 3.32 ± 1.03 3.29 ± 0.81 3.39 ± 0.80 3.65 ± 1.23 0.01
SPPB short physical performance battery. Values are presented as mean ± standard deviation for continuous variables, and n (%) for
categorical variables
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Table 3 reports the clinical characteristics of the
participants according to the FT4 quartile of distribu-
tion. A linear trend in age and weight (p = 0.007 and p =
0.02, respectively) was found through the quartiles. A
linear relationship was also present for physical perfor-
mance (SPPB score Stβ ± SE = − 0.16 ± 0.04) and mus-
cle strength (handgrip Stβ ± SE = 0.14 ± 0.04).
Finally, Table 4 describes the clinical characteristics
of the population according to FT3/FT4 ratios
subdivided in quartiles. The subjects classified in the
lowest quartile were older compared to all other groups,
and consequently, dementia and incontinence were
slightly more prevalent (p = 0.04; p = 0.05, respective-
ly); for the same reason, subjects in this quartile
displayed a lower physical performance (p < 0.001),
strength (p = 0.04), and muscle mass/height squared
ratio (p = 0.04) compared to other quartiles.
Among diseases only diabetes showed higher preva-
lence in the FT3/FT4 ratio lowest quartile of distribution
(p = 0.002), but no association could be foundwith other
THs.
No differences in the frequency of corticosteroid,
anti-hypertensive, inotropic drugs, and methimazole
use were found according to THs quartile of distribution
(data not shown). Levothyroxine was prescribed, more
often to cases in the highest quartile of TSH, compared
to all others (10.6% vs 2.3%; p = 0.003, respectively).
No association with other THs was found for any drug
considered.
In the multivariate analysis, where SPPB score,
strength, and muscle mass/height squared ratio were
analyzed in different models, according to dummy var-
iables derived from FT3, FT4, TSH, and FT3/FT4-ratios
for quartile of distribution, and adjusted for age and sex,
no changes in the significant differences were found
(Table 5).
The lowest and the intermediate-lowest quartiles of
TSH showed a reduction in muscle mass/height squared
ratio, compared to the highest quartile (β ± SE − 1.79 ±
0.78; p = 0.02; β ± SE − 1.64 ± 0.82, respectively). No
differences were found for physical performance and
strength.
Table 2 Descriptive of the population enrolled in the Mugello study according to FT3 (pg/m) quartiles of distribution
FT3 < 2.56 FT3 2.57–2.78 FT 32.79–3.05 FT3 > 3.05
103 100 114 100 p trend
Sex male 24 (23.3) 28 (28.0) 31 (27.2) 28 (28.0) 0.85
Age (yy) 93.37 ± 3.73 93.12 ± 3.12 92.75 ± 2.82 92.80 ± 2.92 0.13
Weight (kg) 62.89 ± 13.31 61.77 ± 12.19 60.80 ± 12.38 62.28 ± 12.57 0.61
Height (m) 1.57 ± 0.09 1.58 ± 0.09 1.57 ± 0.09 1.57 ± 0.10 0.33
Smoke (actually) 23 (22.3) 31 (31.0) 35 (30.7) 24 (24.0) 0.07
Diabetes 20 (19.4) 14 (14.0) 16 (14.0) 7 (6.9) 0.08
Cardiovascular diseases 54 (52.4) 44 (44.0) 47 (41.2) 45 (45.0) 0.47
Respiratory diseases 13 (12.6) 13 (13.0) 21 (18.4) 15 (15.0) 0.71
Cerebrovascular diseases 18 (17.5) 24 (24.0) 16 (14.0) 27 (27.0) 0.07
Dementia 13 (12.6) 12 (12.0) 13 (11.4) 12 (12.0) 0.98
Oncological diseases 52 (50.5) 56 (56.0) 66 (57.9) 53 (53.0) 0.85
SPPB (0–3) 0.87 ± 0.97 1.06 ± 1.10 1.35 ± 1.07 1.37 ± 1.01 < 0.001
Handgrip (kg) 12.92 ± 7.95 13.57 ± 6.07 13.20 ± 6.84 13.91 ± 7.39 0.44
Levothyroxine 9 (8.7) 6 (6.0) 3 (2.6) 0 0.07
Muscle/height2 (kg/m2) 11.34 ± 2.72 11.98 ± 2.49 12.06 ± 3.44 12.46 ± 3.44 0.04
Fat mass (kg) 17.11 ± 9.87 15.87 ± 9.40 14.73 ± 8.30 16.12 ± 10.03 0.36
FT3 (pg/m) 2.35 ± 0.17 2.67 ± 0.06 2.92 ± 0.08 3.45 ± 0.56 < 0.001
FT4 (ng/dL) 0.85 ± 0.21 0.88 ± 0.22 0.86 ± 0.18 0.93 ± 0.28 0.02
TSH (μIU/mL) 3.51 ± 9.75 1.63 ± 1.23 1.87 ± 3.40 1.52 ± 1.37 0.01
FT3/FT4 ratio 2.98 ± 1.08 3.22 ± 0.77 3.53 ± 0.78 3.92 ± 1.05 < 0.001
SPPB short physical performance battery. Values are presented as mean ± standard deviation for continuous variables, and n (%) for
categorical variables
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Similarly, lowest and intermediate-lowest FT3
quartiles showed a reduction in the SPPB score,
compared to the upper quartile, independently from
age and sex (β ± SE − 0.44 ± 0.14; p = 0.002; − 0.29
± 0.14; p = 0.04, respectively). Physical performance
(SPPB score) and strength (handgrip test) were asso-
ciated with FT4 lower and intermediate-lower quar-
tile, independent of age and sex. No differences
among the four quartiles were detectable for muscle
mass/height squared ratio.
The analysis for the FT3/FT4 ratio confirmed that
muscle mass/height squared ratio was lower in low,
intermediate-low, and intermediate-high compared to
the highest quartile. For physical performance, differ-
ences were observed among low and intermediate-low
compared to the highest quartile. Finally, in order to
evaluate the independent but concurrent role of different
markers of thyroid signaling hormones on physical per-
formance, strength, and muscle mass, three separate
linear regression models were analyzed (Table 6 parts
1, 2, and 3).
The lowest quartile of FT3/FT4 ratio, independent of
age and sex, was the only marker associated with SPPB,
accounting for 8% of the 14% of the total variance
explained by the model. Moreover, subjects in this
lowest quartile (FT3/FT4 ratio < 2.75) showed a mean
reduction of physical performance of 0.50 points, com-
pared to all other groups (Table 6 part 1). In the model
that analyzes handgrip, lowest quartile of FT4 (values <
0.73 mg/mL) was associated with a significant increase
in strength (Table 6 part 2). Muscle mass/height squared
ratio was higher, in the highest quartile (values > 3.84)
of the FT3/FT4 ratio (β ± SE = 1.11 ± 0.42; p = 0.009),
compared to all other groups (Table 6 part 3). All the
models were adjusted for age, sex, diabetes,
levothyroxine prescription, and the other THs.
Discussion
This study demonstrates that in a cohort of free-living
nonagenarian subjects, several measures of physical
Table 3 Descriptive of the population enrolled in the Mugello study according to FT4 (ng/dL) quartiles of distribution
FT4 < 0.73 FT4 0.74–0.86 FT4 0.75–1.00 FT4 > 1.00
102 107 105 103 p trend
Sex male 29 (28.43) 21 (19.63) 32 (30.48) 29 (28.16) 0.29
Age (yy) 92.57 ± 2.81 92.76 ± 2.93 92.93 ± 3.18 93.76 ± 3.59 0.007
Weight (kg) 64.96 ± 13.18 60.99 ± 11.64 61.14 ± 12.78 60.52 ± 12.43 0.02
Height (m) 1.58 ± 0.09 1.55 ± 0.08 1.58 ± 0.11 1.57 ± 0.09 0.78
Smoke (actually) 30 (29.41) 30 (28.04) 28 (26.67) 25 (24.27) 0.70
Diabetes 13 (12.8) 9 (8.4) 13 (12.3) 22 (21.4) 0.06
Cardiovascular diseases 42 (41.18) 52 (48.60) 52 (49.52) 44 (42.72) 0.55
Respiratory diseases 18 (17.65) 22 (20.56) 14 (13.33) 8 (7.77) 0.04
Cerebrovascular diseases 19 (18.63) 23 (21.50) 19 (18.10) 24 (23.30) 0.78
Dementia 10 (9.80) 19 (17.76) 11 (10.48) 10 (9.71) 0.18
Oncological diseases 60 (58.82) 55 (51.40) 55 (52.38) 57 (55.34) 0.74
SPPB score (0–3) 1.43 ± 1.03 1.27 ± 1.04 1.06 ± 1.10 0.90 ± 1.00 < 0.001
Handgrip (kg) 14.84 ± 7.61 13.22 ± 6.64 13.33 ± 7.83 12.05 ± 5.85 0.01
Levothyroxine 4 (3.96) 5 (4.8) 2 (1.9) 7 (6.8) 0.37
Muscle/height2 (kg/m2) 12.72 ± 3.16 12.16 ± 2.61 11.54 ± 3.49 11.81 ± 3.00 0.23
Fat mass (kg) 17.35 ± 10.32 15.27 ± 8.06 15.94 ± 9.32 15.20 ± 9.66 0.25
FT3 (pg/m) 2.80 ± 0.50 2.83 ± 0.39 2.83 ± 0.38 2.93 ± 0.65 0.06
FT4 (ng/dL) 0.64 ± 0.09 0.79 ± 0.04 0.93 ± 0.04 1.16 ± 0.22 < 0.001
TSH (μIU/mL) 3.94 ± 10.18 1.73 ± 1.41 1.40 ± 0.99 1.51 ± 1.91 0.001
FT3/FT4 ratio 4.48 ± 1.11 3.59 ± 0.52 3.05 ± 0.43 2.55 ± 0.50 < 0.001
SPPB short physical performance battery. Values are presented as mean ± standard deviation for continuous variables, and n (%) for
categorical variables
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performance and muscle fitness are related to thyroid
hormone levels. Lower free T3/free T4 ratio is associat-
ed with lower SPPB score, and the highest quartile of
FT4 with a higher handgrip test result, whereas the
lowest FT3/FT4 quartile is correlated with higher mus-
cle mass. All these associations were assessed in models
demonstrating their independence from potential con-
founding factors.
The major finding of this study is the association of
low FT3/FT4 ratio and low physical performance, inde-
pendent from the concurrent effect of the other THs, in
an oldest-old population, bridging the gap of available
data.
In the InCHIANTI study, after adjusting for mul-
tiple confounders, an association between physical
performance and FT3, but not FT4 or TSH, was
found [24]. The populations of the InCHIANTI and
the Mugello studies were selected in the same region
(Tuscany), but in the latter, it is represented only by
nonagenarians; the two studies differed also in de-
sign, i.e., a cross-sectional design for the Mugello
study and a longitudinal one for the InCHIANTI.
Moreover, the FT3/FT4 ratio was not analyzed in
the InCHIANTI results. Ceresini et al. found a three-
fold increase in the risk of impaired mobility (defined
by SPPB < 9) in subjects of the InCHIANTI study
with subclinical hyperthyroidism [25]. In a smaller
study of fifty-one elderly fit subjects, levels of thy-
roid hormones (FT3/FT4 ratio) were correlated with
aerobic endurance capacity and strength [26]. Re-
cently, Kong et al., in a Korean population aged
40–69 years, demonstrated that a low FT3/FT4 ratio,
but not serum FT3 or FT4 alone, was associated with
low muscle mass and impaired physical performance
[15]. Serum TSH level was shown to be inversely
correlated with handgrip strength in a large cross-
sectional study in Germany [27]. Other studies failed
to detect a relationship between thyrotropin and per-
formance in elderly subjects [28]. Recently, two
cross-sectional studies of the same cohort of cente-
narians demonstrated that THs were associated with
frailty, disability, and cognitive status [13, 16].
Table 4 Descriptive of the population enrolled in the Mugello study according to FT3/FT4 ratio quartiles of distribution
FT3/FT4 < 2.75 FT3/FT4 2.76–3.32 FT3/FT4 3.33–3.84 FT3/FT4 > 3.84
102 107 105 103 p trend
Sex male 25 (23.81) 35 (32.71) 28 (27.18) 23 (22.55) 0.34
Age (yy) 94.28 ± 3.89 92.64 ± 2.98 92.48 ± 2.48 92.61 ± 2.78 < 0.001
Weight (kg) 60.64 ± 13.39 61.68 ± 11.22 62.32 ± 13.05 62.96 ± 12.68 0.18
Height (m) 1.58 ± 0.09 1.57 ± 0.10 1.57 ± 0.09 1.57 ± 0.08 0.77
Smoke (actually) 20 (19.05) 33 (30.84) 31 (30.10) 29 (28.43) 0.12
Diabetes 26 (24.8) 14 (13.0) 5 (4.9) 12 (11.8) 0.003
Cardiovascular diseases 48 (45.71) 54 (50.47) 47 (45.63) 41 (40.20) 0.51
Respiratory diseases 9 (8.57) 16 (14.95) 15 (14.56) 22 (21.57) 0.10
Cerebrovascular diseases 22 (20.95) 22 (20.56) 21 (20.39) 20 (19.61) 0.97
Dementia 17 (16.19) 5 (4.67) 14 (13.59) 14 (13.73) 0.04
Oncological diseases 51 (48.57) 60 (56.07) 57 (55.34) 59 (57.84) 0.55
SPPB score (0–3) 0.70 ± 0.93 1.20 ± 1.12 1.31 ± 1.02 1.47 ± 1.01 < 0.001
Handgrip (kg) 11.29 ± 6.13 13.98 ± 7.96 14.56 ± 6.75 13.51 ± 7.01 0.04
Muscle (kg) 29.19 ± 8.81 29.20 ± 7.40 28.59 ± 9.08 32.21 ± 9.19 0.08
Muscle/height2 (kg/m2) 11.57 ± 3.06 11.89 ± 2.79 11.64 ± 3.21 12.78 ± 3.19 0.04
Fat mass (kg) 15.89 ± 9.98 14.75 ± 7.86 17.86 ± 9.97 15.26 ± 9.46 0.78
FT3 (pg/m) 2.61 ± 0.45 2.80 ± 0.31 2.89 ± 0.38 3.11 ± 0.65 < 0.001
FT4 (ng/dL) 1.11 ± 0.24 0.92 ± 0.11 0.81 ± 0.11 0.68 ± 0.16 < 0.001
TSH (μIU/mL) 1.62 ± 1.96 1.58 ± 1.20 1.86 ± 3.68 3.52 ± 9.66 0.001
FT3/FT4 ratio 2.37 ± 0.29 3.06 ± 0.16 3.59 ± 0.16 4.68 ± 1.00 < 0.001
SPPB short physical performance battery. Values are presented as mean ± standard deviation for continuous variables, and n (%) for
categorical variables
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Moreover, both the increase of FT4 and the decrease
of the FT3/FT4 ratio were associated with lower
survival [13]. These data are consistent with the
results of our study, since lower level of physical
performance, muscle mass reduction, and lower mus-
cle strength are components of the frailty phenotype
[29]. In addition, a decrease of the SPPB score is a
strong predictor of subsequent disability [2] and also
of catastrophic events such as institutionalization or
death [22].
Skeletal muscle is a target of thyroid hormone sig-
naling, acting on muscle contractility and metabolism,
by regulating gene expression in an age-dependent man-
ner [30]. Thyroid hormone–converting enzymes (DIO2
and DIO3) locally control the uptake and the activation
or inactivation of TH within the skeletal muscle tissue.
Table 5 Linear regression analysis, associations of physical performance (SPPB score), strength (handgrip), and muscle mass/height
squared ratio with quartiles of distribution of thyroid hormones
SPPB Handgrip Muscle/H2
β ± SE p value β ± SE p value β ± SE p value
A
Intercept 9.14 ± 1.48 < 0.001 61.09 ± 9.15 < 0.001 32.78 ± 8.56 < 0.001
TSH < 0.79 − 0.01 ± 0.14 0.95 0.33 ± 0.86 0.70 − 1.79 ± 0.78 0.02
TSH 0.80–1.25 0.05 ± 0.14 0.74 0.32 ± 0.86 0.71 − 1.64 ± 0.82 0.04
TSH 1.26–2.11 0.01 ± 0.14 0.99 1.01 ± 0.86 0.24 − 1.01 ± 0.78 0.20
TSH > 2.11 Reference
Age (yy) − 0.08 ± 0.02 < 0.001 − 0.45 ± 0.09 < 0.001 − 0.11 ± 0.09 0.25
Sex (female) − 0.33 ± 0.11 0.004 − 8.33 ± 0.67 < 0.001 − 4.16 ± 0.62 < 0.001
B
Intercept 8.96 ± 1.46 < 0.001 62.23 ± 9.11 < 0.001 31.17 ± 8.50 < 0.001
FT3 < 2.56 − 0.44 ± 0.14 0.002 − 0.38 ± 0.86 0.66 − 1.46 ± 0.80 0.07
FT3 2.57–2.78 − 0.29 ± 0.14 0.04 − 0.44 ± 0.88 0.62 − 0.67 ± 0.83 0.42
FT32.79–3.05 − 0.03 ± 0.14 0.84 − 0.68 ± 0.82 0.40 − 0.53 ± 0.78 0.50
FT3 > 3.05 Reference
Age (yy) − 0.08 ± 0.02 < 0.001 − 0.46 ± 0.10 < 0.001 − 0.09 ± 0.09 0.30
Sex (female) − 0.33 ± 0.11 0.004 − 8.33 ± 0.67 < 0.001 − 4.01 ± 0.62 < 0.001
C
Intercept 8.30 ± 1.48 < 0.001 58.21 ± 9.09 < 0.001 30.35 ± 8.61 < 0.001
FT4 < 0.73 0.44 ± 0.14 0.002 2.57 ± 0.85 0.003 0.78 ± 0.78 0.32
FT4 0.74–0.86 0.32 ± 0.14 0.02 1.62 ± 0.84 0.05 0.55 ± 0.79 0.49
FT4 0.75–1.00 0.09 ± 0.14 0.51 0.61 ± 0.86 0.48 − 0.42 ± 0.79 0.59
FT4 > 1.01 Reference
Age (yy) − 0.08 ± 0.02 < 0.001 − 0.43 ± 0.10 < 0.001 − 0.09 ± 0.09 0.30
Sex (female) − 0.36 ± 0.11 0.002 − 8.45 ± 0.66 < 0.001 − 4.10 ± 0.63 < 0.001
D
Intercept 7.98 ± 1.47 < 0.001 57.54 ± 9.20 < 0.001 19.48 ± 5.55 < 0.001
FT3/FT4 < 2.75 − 0.67 ± 0.14 < 0.001 − 1.95 ± 0.86 0.03 − 1.14 ± 0.51 0.02
FT3/FT4 2.76–3.32 − 0.31 ± 0.14 0.02 − 0.77 ± 0.84 0.35 − 1.07 ± 0.51 0.03
FT3/FT4 3.33–3.84 − 0.19 ± 0.14 0.17 0.34 ± 0.83 0.35 − 1.11 ± 0.51 0.03
FT3/FT4 > 3.84 Reference
Age (yy) − 0.07 ± 0.02 < 0.001 − 0.41 ± 0.10 < 0.001 − 0.06 ± 0.06 0.33
Sex (female) − 0.35 ± 0.11 0.002 − 8.39 ± 0.66 < 0.001 − 1.71 ± 0.39 < 0.001
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Table 6 Backward multiple linear regression analysis assessing the association between physical performance, muscle strength, andmuscle
mass/height squared ratio and thyroid hormone signaling
Model A Model B
β ± SE p value β ± SE p value
1. SPPB score
Intercept 7.73 ± 1.49 < 0.001 7.70 ± 1.49 < 0.001
TSH < 0.79 (lowest quartile) 0.01 ± 0.11 0.97
TSH > 0.79 Reference
FT3 < 2.56 (lowest quartile) − 0.25 ± 0.12 0.03
FT3 > 2.56 Reference
FT4 < 0.73 (lowest quartile) 0.21 ± 0.12 0.09
FT4 > 0.73 Reference
FT3/FT4 < 2.75 (lowest quartile) − 0.35 ± 0.13 0.001 − 0.49 ± 0.12 < 0.001
FT3/FT4 > 2.75 Reference
R2 0.14 0.13
AIC − 0.900 − 0.544
RSSE 395.5 398.7
2. Handgrip test
Intercept 57.94 ± 9.31 < 0.001 57.71 ± 9.13 < 0.001
TSH < 0.79 (lowest quartile) 0.07 ± 0.71 0.92
TSH > 0.79 Reference
FT3 < 2.56 (lowest quartile) 0.38 ± 0.76 0.62
FT3 > 2.56 Reference
FT4 < 0.73 (lowest quartile) 1.42 ± 0.73 0.05 1.78 ± 0.68 0.009
FT4 > 0.73 Reference
FT3/FT4 < 2.75 (lowest quartile) − 1.13 ± 0.84 0.18
FT3/FT4 > 2.75 Reference
R2 0.38 0.38
AIC 1248.4 1244.3
RSSE 11,131 11,189
3. Muscle mass/height squared ratio
Intercept 19.01 ± 5.63 0.001 19.04 ± 5.40 < 0.001
TSH < 0.79 (lowest quartile) − 0.67 ± 0.41 0.09
TSH > 0.79 Reference
FT3 < 2.56 (lowest quartile) − 0.48 ± 0.43 0.26
FT3> 2.56 Reference
FT4 > 1.01 (lowest quartile) − 0.32 ± 0.52 0.54
FT4 < 1.01 Reference
FT3/FT4 > 3.84 (highest quartile) 1.20 ± 0.55 0.03 1.11 ± 0.42 0.009
FT3/FT4 < 3.84 Reference
R2 0.11 0.10
AIC 621.3 619.2
RSSE 2380.5 2419.5
In all the models, thyroid hormones were dummy categorized and were adjusted for age, sex, diabetes, and levothyroxine therapy and were
not excluded from the analysis even if they did not reach a statically significant level. Model A saturated model; Model B parsimonious
model
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Muscle gene expression, phenotype, plasticity, energy
turnover, and glucose metabolism are controlled and
regulated in a T3-dependent fashion [14]. During aging,
changes occurring in the thyroid structure and function
affect TH production, metabolism, transport, and action;
tissue-specific regulation of deiodinase activities occurs
with aging, but TH signaling in the muscle, heart, and
brain appears to be unaltered [31].
Recently Franceschi et al., reviewing the complex
interrelationship among aging, longevity, and thyroid
aging, highlighted how complex and heterogeneous
are those traits interactions, particularly in the oldest-
old [32]. Moreover, they suggested that similar to
inflammaging or to osteoporosis, also those thyroid
age–related changes could be part of the “systemic
adaptive remodeling” that had the function to prevent
or mitigate processes of tissue disruption and degenera-
tive changes [33].
Therefore, our results need to be evaluated keeping in
mind those two postulates. First, the cross-sectional
character of the study does not consider the interaction
of lifelong internal and external factors leading to indi-
vidual heterogeneity. Second, changes occurring during
thyroid aging might be considered adaptive, and not
only detrimental.
Collectively this data indicate the FT3/FT4 ratio as a
possible marker of muscle aging, even if the action of
THs on several target organs and their functions may
play a role in modulating physical performance and
strength.
To the best of our knowledge, this is the first study
assessing the concurrent role of the different THs in a
large population of nonagenarians, and showing the
relationship of the FT3/FT4 ratio with aging muscle
function.
Among the limitations due to the cross-sectional
design, this study could only detect associations be-
tween TH and markers of muscle aging, and not a
causal relationship. Recall bias, frequent in elderly
subjects in the Mugello study were overcome with
the required presence of the caregiver during the
clinical session. Moreover, as suggested by Maggio
et al., individual hormones do not operate indepen-
dent of each other; rather, one hormonal problem
may trigger the onset of another [34, 35], such that
associations between individual hormones and health
status may result from a wider hormonal dysfunction
or from concurrent effects on other physiological
systems.
Conclusion
In a population of (free-living) nonagenarians, levels of
thyroid hormones have been shown to play a central role
in the variation of physical performance and muscle
strength, which are key markers of the aging process.
We could not establish whether the FT3/FT4 ratio may
be a marker of successful aging or just an epiphenome-
non of the aging muscle. Longitudinal evaluations are
required to verify these findings and elucidate the path-
way(s) linking thyroid and muscle function in aging.
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